InnoBooster 2023

• TetraKit Technologies received an InnoBooster grant from Innovation Fund Denmark, supporting early-stage innovation with strong commercial potential.

Eurostars 2023

• Eurostars funds the αTREAT project and has also agreed to partially fund a First-in-Human diagnostic study to accelerate the development of a novel PSMA-targeted therapy for metastatic prostate cancer. This collaboration brings together TetraKit, Elysia-Raytest, and Rigshospitalet’s expertise in radiopharmaceutical technology and astatine-211 production.

Eurostars 2024

• €1 million awarded for the PRE-CISE project (2025–2027), in collaboration with Akiram Therapeutics and PreTT, to develop targeted alpha therapies using an innovative pretargeting system. Read more about the collaboration here: https://shorturl.at/liJ1q

Grand Solutions 2024

• TetraKit is proud to be part of the AstraTATE project, supported by Innovation Fund Denmark with 21.7 million DKK. This initiative is focused on developing a targeted alpha therapy utilizing astatine-211 for the treatment of neuroendocrine tumors, with the goal of delivering a safer and more effective cancer therapy. Read more about the project here (Danish): https://shorturl.at/6QmSJ

Industrial Postdoc Fellowship 2024

• TetraKit received the Industrial Postdoc Fellowship 2024 from Innovation Fund Denmark, supporting advanced research with a strong focus on industry collaboration and innovation.